Oppenheimer analyst Silvan Tuerkcan lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $40.00) while maintaining a Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Exelixis (EXEL) PT Raised to $33 at Needham & CompanyFebruary 13, 2019 10:52 AM Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q February 13, 2019 10:01 AM Exelixis (EXEL) PT Lowered to $34 at RBC CapitalFebruary 13, 2019 6:38 AM Exelixis (EXEL) to Initiate Phase 1 Clinical Development of XL092February 12, 2019 4:14 PM Exelixis (EXEL) Tops Q4 EPS by 13cFebruary 12, 2019 4:07 PM Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateFebruary 12, 2019 4:06 PM Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery EffortsFebruary 12, 2019 4:05 PM